New York Sports NutOrexigen Declines on Review Delay for Weight-Loss PillBloombergOrexigen Therapeutics Inc. (OREX) fell the most in three years after regulators pushed back a decision on whether to approve the company’s obesity drug NB32. The shares dropped 17 percent to $5.65 at 9:36 a.m. New York time, after plunging to $5.45 in …FDA Postpones Approval of Contrave: What’s The Future Of Weight Loss Drugs?ForbesFDA Delays Action on Orexigen’s Anti-Obesity Drug by 3 MonthsXconomyFDA pauses Orexigen drug approvalMedical Marketing and MediaTechsonia -Businessweek -New York Sports Nutall 79 news articles …Read Full Story
Orexigen Declines on Review Delay for Weight-Loss Pill - Bloomberg
Real Estate of Cebu
